Cargando…

CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy

Brachytherapy is one mainstay treatment for lung cancer. However, a great challenge in brachytherapy is radio-resistance, which is caused by severe hypoxia in solid tumors. In this research, we have developed a PEGylated (131)I-labeled CuS nanotheranostics (CuS-(131)I-PEG)-induced “multiple mild-hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yanna, Yan, Hui, Wang, Haoze, Zhang, Yongming, Li, Meng, Cui, Kai, Xiao, Zeyu, Liu, Liu, Xie, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785376/
https://www.ncbi.nlm.nih.gov/pubmed/36559162
http://dx.doi.org/10.3390/pharmaceutics14122669
_version_ 1784858033399005184
author Cui, Yanna
Yan, Hui
Wang, Haoze
Zhang, Yongming
Li, Meng
Cui, Kai
Xiao, Zeyu
Liu, Liu
Xie, Wenhui
author_facet Cui, Yanna
Yan, Hui
Wang, Haoze
Zhang, Yongming
Li, Meng
Cui, Kai
Xiao, Zeyu
Liu, Liu
Xie, Wenhui
author_sort Cui, Yanna
collection PubMed
description Brachytherapy is one mainstay treatment for lung cancer. However, a great challenge in brachytherapy is radio-resistance, which is caused by severe hypoxia in solid tumors. In this research, we have developed a PEGylated (131)I-labeled CuS nanotheranostics (CuS-(131)I-PEG)-induced “multiple mild-hyperthermia” strategy to reverse hypoxia-associated radio-resistance. Specifically, after being injected with CuS-(131)I-PEG nanotheranostics, tumors were irradiated by NIR laser to mildly increase tumor temperature (39~40 °C). This mild hyperthermia can improve oxygen levels and reduce expression of hypoxia-induced factor-1α (HIF-1α) inside tumors, which brings about alleviation of tumor hypoxia and reversion of hypoxia-induced radio-resistance. During the entire treatment, tumors are treated by photothermal brachytherapy three times, and meanwhile mild hyperthermia stimulation is conducted before each treatment of photothermal brachytherapy, which is defined as a “multiple mild-hyperthermia” strategy. Based on this strategy, tumors have been completely inhibited. Overall, our research presents a simple and effective “multiple mild-hyperthermia” strategy for reversing radio-resistance of lung cancer, achieving the combined photothermal brachytherapy.
format Online
Article
Text
id pubmed-9785376
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97853762022-12-24 CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy Cui, Yanna Yan, Hui Wang, Haoze Zhang, Yongming Li, Meng Cui, Kai Xiao, Zeyu Liu, Liu Xie, Wenhui Pharmaceutics Article Brachytherapy is one mainstay treatment for lung cancer. However, a great challenge in brachytherapy is radio-resistance, which is caused by severe hypoxia in solid tumors. In this research, we have developed a PEGylated (131)I-labeled CuS nanotheranostics (CuS-(131)I-PEG)-induced “multiple mild-hyperthermia” strategy to reverse hypoxia-associated radio-resistance. Specifically, after being injected with CuS-(131)I-PEG nanotheranostics, tumors were irradiated by NIR laser to mildly increase tumor temperature (39~40 °C). This mild hyperthermia can improve oxygen levels and reduce expression of hypoxia-induced factor-1α (HIF-1α) inside tumors, which brings about alleviation of tumor hypoxia and reversion of hypoxia-induced radio-resistance. During the entire treatment, tumors are treated by photothermal brachytherapy three times, and meanwhile mild hyperthermia stimulation is conducted before each treatment of photothermal brachytherapy, which is defined as a “multiple mild-hyperthermia” strategy. Based on this strategy, tumors have been completely inhibited. Overall, our research presents a simple and effective “multiple mild-hyperthermia” strategy for reversing radio-resistance of lung cancer, achieving the combined photothermal brachytherapy. MDPI 2022-11-30 /pmc/articles/PMC9785376/ /pubmed/36559162 http://dx.doi.org/10.3390/pharmaceutics14122669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cui, Yanna
Yan, Hui
Wang, Haoze
Zhang, Yongming
Li, Meng
Cui, Kai
Xiao, Zeyu
Liu, Liu
Xie, Wenhui
CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title_full CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title_fullStr CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title_full_unstemmed CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title_short CuS-(131)I-PEG Nanotheranostics-Induced “Multiple Mild-Hyperthermia” Strategy to Overcome Radio-Resistance in Lung Cancer Brachytherapy
title_sort cus-(131)i-peg nanotheranostics-induced “multiple mild-hyperthermia” strategy to overcome radio-resistance in lung cancer brachytherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785376/
https://www.ncbi.nlm.nih.gov/pubmed/36559162
http://dx.doi.org/10.3390/pharmaceutics14122669
work_keys_str_mv AT cuiyanna cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT yanhui cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT wanghaoze cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT zhangyongming cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT limeng cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT cuikai cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT xiaozeyu cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT liuliu cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy
AT xiewenhui cus131ipegnanotheranosticsinducedmultiplemildhyperthermiastrategytoovercomeradioresistanceinlungcancerbrachytherapy